“We need to be able to tolerate the ambiguity of not having a clear path forward and a willingness to define that path in an area where the stakes are high.”
Katrine Bosley is the Chairman of the Board of Arrakis Therapeutics. She also serves as a Board member of Galapagos NV, of Genocea Biosciences and of the Mass Eye and Ear Institute.
Bosley is an entrepreneur who has built products and companies in the biotech industry for nearly 30 years. Through her career, Ms. Bosley has built and led high-growth companies and developed innovative products and technologies. She served as the Chief Executive Officer of Editas Medicine Inc., a genome editing company, from shortly after its inception through its IPO and entry into clinical development. Prior to Editas, Bosley was the Entrepreneur-in-Residence at The Broad Institute and was Chief Executive Officer of Avila Therapeutics. Before Avila, she was Vice President, Strategic Operations at Adnexus Therapeutics, a Bristol-Myers Squibb Company, and was Vice President, Business Development at Adnexus prior to that. She joined Adnexus from Biogen where she held roles in business development, commercial operations, and portfolio strategy in the United States and Europe.
Bosley has been recognized as one of the 100 Most Creative People in Business by Fast Company, as CEO of the Year by Xconomy, as one of 30 Global Game Changers by Forbes, as Entrepreneur of the Year by the New England Venture Capital Association, and as one of the Top Ten Women in Biotech by FierceBiotech.
Bosley graduated from Cornell University with a B.A. in biology as a College Scholar and completed the Program for Management Development at Harvard Business School.